The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases
详细信息 查看全文
- 作者：Ana Luisa Neves1 ; Julien Chilloux1 ; Magali H Sarafian ; Mohd Badrin Abdul Rahim ; Claire L Boulangé ; 2 ; Marc-Emmanuel Dumas m.dumas@imperial.ac.uk" class="auth_mail" title="E-mail the corresponding author
- 关键词：Acetate (PubChem CID ; 176) ; Butyrate (PubChem CID ; 264) ; Cholic acid (PubChem CID ; 221493) ; Chenodeoxycholic acid (PubChem CID ; 10133) ; Deoxycholic acid (PubChem CID ; 222528) ; Indole-3-propionate (PubChem CID ; 3744) ; 3-indoxylsulfate (PubChem CID ; 10258) ; Propionate (PubChem CID ; 1032) ; Trimethylamine (PubChem CID ; 1146) ; Trimethylamine-N-oxide (PubChem CID ; 1145)
- 刊名：Current Opinion in Pharmacology
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：25
- 期：Complete
- 页码：36-44
- 全文大小：931 K
文摘
- •
Gut microbiota communicates with its mammalian host via microbial signalling metabolites.
- •
Disease phenotypes can be modulated by microbiome intervention.
- •
Microbial signalling metabolites impact signalling networks involved in disease.
- •
Designing microbiome-inspired drugs is a promising strategy.